5 citations,
January 2020 in “Skin appendage disorders” Oral dutasteride works better for hair loss, but has more sexual side effects; intralesional dutasteride is a possible alternative.
18 citations,
February 2016 in “The Journal of Clinical Endocrinology and Metabolism” Advancements in male reproductive medicine are ongoing, but more research and improved treatments are needed in several areas.
January 2020 in “Archives of urology” Finasteride, a drug used for certain conditions, can cause serious side effects like sexual dysfunction, suicidal thoughts, and increased diabetes risk, and there's a need for more awareness and research about these effects.
54 citations,
May 2018 in “Journal of The European Academy of Dermatology and Venereology” Low level laser therapy works best for hair loss, followed by PRP, finasteride, and minoxidil.
2 citations,
December 2019 in “Journal of Dermatological Treatment” Metabolic syndrome reduces effectiveness of hair loss treatment.
17 citations,
June 2012 in “Australasian Journal of Dermatology” Finasteride and low-dose dutasteride combo improves hair growth and reduces hair loss with no major side effects.
50 citations,
September 2016 in “The Journal of Clinical Endocrinology and Metabolism” Finasteride for hair loss may cause persistent sexual symptoms, depression, anxiety, and lower quality of life.
24 citations,
December 2013 in “Sexual medicine reviews” Finasteride can cause sexual problems and depression in young men.
81 citations,
March 2009 in “Seminars in Cutaneous Medicine and Surgery” Effective hair loss treatment in women requires correct diagnosis and can include medications like minoxidil, antiandrogens, and treatments for underlying conditions like PCOS.
47 citations,
April 2017 in “European Journal of Pharmaceutics and Biopharmaceutics” The new dutasteride formula can be applied to the skin, may promote hair growth, and has fewer side effects.
36 citations,
June 2018 in “Journal of Dermatology” Use finasteride, dutasteride, and minoxidil for hair loss treatment.
4 citations,
March 2018 in “Daehan han'yi hag'hoeji/Journal of Korean medicine” Astragalus membranaceus helps regrow hair and reduce hair loss symptoms.
November 2009 in “Cambridge University Press eBooks” Minoxidil and finasteride combined can effectively treat hair loss.
110 citations,
August 2016 in “Drugs” Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.
212 citations,
September 2008 in “Journal of The American Academy of Dermatology” Minoxidil and finasteride treat hair loss in men, while minoxidil treats hair loss in women.
17 citations,
January 2015 in “MedChemComm” New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.
124 citations,
March 2012 in “JAMA” Testosterone's muscle-building effects do not require its conversion to DHT.
215 citations,
November 2006 in “Journal of The American Academy of Dermatology” Dutasteride more effective for hair growth, but has more side effects than finasteride.
35 citations,
April 2013 in “Sexual medicine reviews” 5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.
October 2006 in “Aging Health” Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.
June 2001 in “International Journal of Cosmetic Surgery and Aesthetic Dermatology” Finasteride improves hair growth in men with androgenetic alopecia.
12 citations,
July 2020 in “International Journal of Pharmaceutics” Iron oxide nanoparticles improve skin penetration and drug release for hair loss treatment.
35 citations,
October 2004 in “Biology of Reproduction” PNU157706 reduced rat sperm movement and fertility without affecting offspring health.
4 citations,
October 2018 in “International Braz J Urol” Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.
1 citations,
April 2019 in “Clinical Breast Cancer” Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.
44 citations,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
49 citations,
January 2004 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.
75 citations,
January 2014 in “Korean Journal of Urology” 5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
1 citations,
August 2015 in “Current Sexual Health Reports” 5α-reductase inhibitors can cause serious and possibly lasting sexual and psychological side effects.
January 2016 in “Archivio italiano di urologia, andrologia” The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.